Detection of short-term chromosomal damage due to therapeutic 131I exposure in patients with thyroid cancer;Detección de daño cromosómico a corto plazo, debido a exposición terapéutica a 131I en pacientes con cáncer de tiroides

Revista de Investigacion Clinica

Volumn 62, Issue 1, 2010, Pages 31-38

  Hernández Jardines, Angélica ^a   Molina, Bertha ^a   Del Castillo, Victoria ^a   Papadakis, Miguel ^b   Rivera, Teodoro ^c   Azorín, Juan ^c   Herrera, Luis A ^d   Yokoyama, Emiy ^a   Frías, Sara ^a  

^a INSTITUTO NACIONAL DE PEDIATRÍA   (Mexico)

^b INSTITUTO NACIONAL DE ENFERMEDADES RESPIRATORIAS   (Mexico)

^c DEPARTAMENTO DE QUÍMICA   (Mexico)

^d UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

Author keywords

131I, thyroid cancer; Chromosomal aberrations; Human lymphocytes; Radiation

Indexed keywords

CALCIUM SULFATE; DYSPROSIUM; IODINE 131;

ADOLESCENT; ADULT; ARTICLE; BLOOD SAMPLING; CANCER TISSUE; CHROMOSOME ABERRATION; CLINICAL ARTICLE; FEMALE; HUMAN; HUMAN CELL; METASTASIS; PERIPHERAL LYMPHOCYTE; RADIATION DOSE; RADIATION EXPOSURE; RADIOISOTOPE THERAPY; THERMOLUMINESCENCE DOSIMETRY; THYROID CANCER; THYROIDECTOMY;

ADULT; CHROMOSOME ABERRATIONS; CHROMOSOME BREAKAGE; CHROMOSOMES, HUMAN; COMBINED MODALITY THERAPY; FEMALE; HUMANS; IODINE RADIOISOTOPES; LYMPHATIC METASTASIS; LYMPHOCYTES; MIDDLE AGED; RADIOPHARMACEUTICALS; THERMOLUMINESCENT DOSIMETRY; THYROID NEOPLASMS; THYROIDECTOMY;

EID: 77952127599     PISSN: 00348376     EISSN: 00348376     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Mäenpää HO, Heikkonen J, Vaalavirta L, Tenhunen M, Joensuu H. Low vs. High Radioiodine Activity to Ablate the Thytoid after Thyroidectomy for Cancer: a Randomized Study, PloS. ONE. 3 (2008): e1885. (Pubitemid 351943823)
2. Black BM, Wooner LB, Blackburn CM. The Uptake of radioactive iodine by carcinoma of thyroid gland: a study of 128 cases. J Clin Endocrinol Metab 1953; 13: 1378-1390
3. Doi SA, Woodhouse NJ, Thalib L, Onitilo A. Ablation of the Thyroid Remnant and I-131 Dose in Differentiated Thyroid Cancer: a Meta-Analysis Revisited. Clin Med Res 2007; 5: 87-90.
4. Jonklaas J. Role of radioactive iodine for adjuvant therapy and treatment. J Natl Compr Canc Netw 2007; 5: 631-640 (Pubitemid 47057052)
5. Brill AB, Stabin M, Bouville A, Ron E. Normal Organ radiation dosimetry and associated uncertainties in nuclear medicin, with emphasis on iodine-131. Radiat Res 2006; 166: 128-140 (Pubitemid 44051206)
6. Raza H, Khan AU, Hameed A, Khan A. Quantitative evaluation of salivary gland dysfunction after radioiodine therapy using salivary gland scintigraphy. Nucl Med Commun 2006; 27: 495-499 (Pubitemid 44309710)
7. Bushnell DL, Boles MA, Kaufman GE, Wadas MA, Barnes WE. Complications, sequela and dosimetry of iodine 131 therapy for thyroid carcinoma. J Nucl Med 1992; 33: 2214-2221
8. Sawka AM, Lakra DC, Lea J, Alshehri B, Tsang RW, Brierley JD, et al. A Systematic review examining the effects of therapeutic radioactive iodine on ovarian function and future pregnancy in female thyroid cancer survivors. Clin Endocrinol (Oxf) 2008; 69: 479-490
9. Krassas GE, Perros P. Thyroid disease and male reproductive function. J Endocrinol Invest 2003; 26: 372-380 (Pubitemid 36763699)
10. Pacini F, Gasperi M, Fugazzola L, Ceccarelli C, Lippi F, Centoni R, et al. Testicular function in patients with differentiated thyroid carcinoma treated with radioiodine. J Nucl Med 1994; 35: 1418-1422 (Pubitemid 24280445)
11. Subramanian S, Goldstein DP, Parlea L, Thabane L, Ezzat S, Ibrahim-Zada I, et al. Second primary malignancy risk in thyroid cancer survivors: a systematic review and meta-analysis. Thyroid 2007; 17: 1277-1288
12. Goodhead DT. Initial events in the cellular effects of ionizing radiations: clustered damage in DNA. Int J Radiat Biol 1994; 65: 7-17.
13. Moore RC, Bender MA. Time sequence of events leading to chromosomal aberration formation. Environ Mol Mutagen 1993; 22; 208-213
14. Livingston GK, Foster AE, Elson HR. Effect of in vivo exposure to iodine-131 on the frequency and persistence of micronuclei in human lymphocytes. J Toxicol Environ Health 1993; 40: 367-375
15. eff) for patients with thyroid cancer. Health Phys 2006; 91: 119-122 (Pubitemid 44086651)
16. 131I in two groups of thyroid cancer patients, Tumori 1987; 73: 257-262 (Pubitemid 17110670)
17. Baugnet-Mahier L, Lemaire M, Léonard E, Léonard A, Gerber G. Chromosome aberrations after treatment with radioactive iodine for thyroid cancer. Radiat Res 1994; 140: 429-431 (Pubitemid 24381492)
18. Monteiro GO, Oliveira NG, Rodrigues AS, Laires A, Ferreira TC, Limbert E, et al. Cytogenetic alterations and oxidative stress in thyroid cancer patients after iodine-131 therapy. Mutagenesis 2000; 15: 69-75. (Pubitemid 30071763)
19. Boyd E, Buchanan W, Lennox B. Damage to chromosomes by therapeutic doses of radioiodine. The Lancet 1961; 277: 977-978
20. Ramírez MJ, Puerto S, Galofré P, Parry EM, Parry JM, Creus A, et al. Multicolour FISH detection of radioactive iodine-induced 17cen-p53 chromosomal breakage in buccal cells from therapeutically exposed patients. Carcinogenesis 2000; 21: 1581-1586 (Pubitemid 30601649)
21. Gundy S, Katz N, Füzy M, Ézik O. Cytogenetic study of radiation burden in thyroid disease patients treated with external irradiation or radioiodine. Mutat Res 1996; 360: 107-113 (Pubitemid 26199678)
22. Joseph LJ, Bhartiya US, Raut YS, Kand P, Hawaldar RW, Nair N. Micronuclei frequency in peripheral blood lymphocytes of thyroid cancer patients after radioiodine therapy and its relationship with metastasis. Mutat Res 2009; 675: 35-40.
23. Im M, Lee JK, Hong YJ, Hong SI, Kang HJ, Na II, et al. Four cases of hematologic malignancy following radioactive iodine therapy for thyroid cancer. Korean J Lab Med 2008; 28: 425-429